

# SUBMISSION FORM FOR RESEARCH INVOLVING HUMAN SUBJECTS

IRB use only: #

Date:

**Instructions:** This form must be filled out completely. Incomplete forms will be returned. A copy of the research proposal and instruments are required. Submit the form in Word format and the proposed research project as a PDF document to the Chicago Department of Public Health Institutional Review Board (CDPH IRB) staff (see below).

| Principal Investigator of Proje | ct:          |                      |          |
|---------------------------------|--------------|----------------------|----------|
| Last Name:                      | First Name:  |                      |          |
| Principal Investigator Title:   |              |                      |          |
| Mailing Address:                |              |                      |          |
| Address                         | City         | State                | Zip Code |
| Email Address:                  |              |                      |          |
| Telephone Number:               | Other Phone: |                      |          |
| Co-Investigator:                |              |                      |          |
| Last Name:                      | First N      | First Name:          |          |
|                                 |              |                      |          |
| CDPH Sponsor:                   |              |                      |          |
| Project Title:                  |              |                      |          |
|                                 |              |                      |          |
| Funding Agency or Research S    | ponsor:      |                      |          |
| Unfunded                        | CDPH Funded  | Other, specify below | :        |

Estimated start date:

Estimated completion date:

Total number of patients to be recruited into project:

Total number of CDPH patients to be recruited into project:

#### 2) Project Description:

(Briefly describe objectives, design, and CDPH-specific operational plan for proposed research. Attach study protocol.)

#### 3) This project will be conducted at the following site(s):

(Please specify which site, on the line provided.)

CDPH clinic(s):

CPPH field site(s):

In the field (non/CDPH clinical or CDPH field site):

Cermak Health Services/Cook County Jail (requires Hektoen IRB approval):

Other (specify):

## A) Exemptions, Waiver or Alteration of Informed Consent and Expedited Review

Check box if you are requesting one of the following: (if not exemption, waiver or alteration, please go to next section). Please refer to exempt research (§46.104) in the <u>revised Common Rule</u>.

(I) Exemption from Review: Check the box below to indicate which category of exempt research this research consists of:

**Category 1:** Research conducted in a commonly accepted academic setting involving normal educational practices that are unlikely to have an adverse effect on students.

**Category 2:** Research solely involving the use of standardized educational tests, survey procedures, interview procedures, or the observation of public behavior and research involving benign behavioral interventions related to the collection of data from an adult human subject through verbal or written responses or audiovisual recording if the human subject agrees to such intervention and collection of data if at least one of the following requirements is met:

- i. The PI records the obtained information in a way that protects the human subjects' identifiable private information
- ii. Any disclosure of the human subjects' information outside the research would not place them at risk of criminal or civil liability or damage their financial standing, employment opportunities, educational advancement, or reputation
- iii. The PI records the information in a way that the human subjects' identity may be readily ascertained, and the CDPH IRB conducts a limited review to make the determination

**Category 3:** Research involving the deception of the human subjects regarding the nature or purposes of the research, if the human subject authorizes, in writing, such deception and acknowledges they will be unaware of or misled regarding the nature and purposes of the research.

**Category 4:** Secondary research when consent is not required and uses identifiable private information or identifiable biospecimens, if at least one of the following requirements is met:

- i. Information being used is publicly available
- ii. The PI records the information in such a way that protects the human subjects' identifiable private information, and the PI does not contact or re-identify the human subjects
- iii. The research involves only information collection and analysis involving the investigator's use of identifiable health information when that use is regulated under 45 CFR parts 160 and 164, subparts A and E, for the purposes of "health care operations" or "research" as those terms are defined at 45 CFR 164.501 or for "public health activities and purposes" as described under 45 CFR 164.512(b).

**Category 5:** Research in which human subjects are elected or appointed public officials or candidates for public office.

**Category 6:** Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the PI in such a manner that human subjects cannot be identified directly or through identifiers linked to the research.

**Category 7:** Research and demonstrations research which are conducted by or subjected to approval of governmental department or agency heads, and which are designed to study, evaluate or otherwise examine:

- i. Public benefit or service programs and possible changes or alternatives to those programs or procedures
- ii. Possible changes in methods or levels of payment for benefits or services under those programs, or
- iii. Taste and food quality evaluation and consumer acceptance studies

If your research does not fit into the exempt categories above, it may be eligible for expedited review (see section III)

(II) Waiver or Alteration of Informed Consent: If you are requesting a waiver or alteration of informed consent, please provide details if the justifications below are met.

May be available if: (i) the research involves no more than minimal risk to the subjects; (ii) the research could not practicably be carried out without the requested waiver or alteration; (iii) if the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or biospecimens in an identifiable format; (iv) the waiver or alteration will not adversely affect the rights and welfare of the subjects; and (v) whenever appropriate, the subjects or legally authorized representatives will be provided with additional pertinent information after participation.

**(III) Expedited Review:** for certain kinds of research involving no more than minimal risk, and for minor changes in approved research.

May be available to review (i) a study involving one or more of eight categories of research listed by the Department of Health and Human Services (HHS) Office of Human Research Protections (OHRP) for expedited review unless the reviewer determines there is more than minimal risk, (ii) minor changes in previously approved research during the period for which approval is authorized, or research for which limited IRB review is a condition of exemption.

The eight research categories listed below and can be found on the Office of Human Research Protection's website linked <u>here</u>:

- I. Clinical studies of drugs and medical devices only when condition (a) or (b) is met.
  - 1. (a) Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.)
  - 2. Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required; or (ii) the medical device is cleared/ approved for marketing and the medical device is being used in accordance with its cleared/approved labeling.
- II. Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
  - 1. from healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the amounts drawn may not exceed 550 ml in an 8 week period and collection may not

occur more frequently than 2 times per week; or

2. from other adults and children [2], considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more frequently than 2 times per week.

III. Prospective collection of biological specimens for research purposes by noninvasive means. Examples: (a) hair and nail clippings in a nondisfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; (c) permanent teeth if routine patient care indicates a need for extraction; (d) excreta and external secretions (including sweat); (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery; (g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; (j) sputum collected after saline mist nebulization.

IV. Collection of data through noninvasive procedures (not involving general anesthesia or sedation) routinely employed in clinical practice, excluding procedures involving x-rays or microwaves. Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.) Examples: (a) physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy; (b) weighing or testing sensory acuity; (c) magnetic resonance imaging; (d) electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography; (e) moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.

V. Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected solely for nonresearch purposes (such as medical treatment or diagnosis). (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. <u>45 CFR 46.101(b)(4)</u>. This listing refers only to research that is not exempt.)

VI. Collection of data from voice, video, digital, or image recordings made for research purposes.

VII. Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. <u>45 CFR 46.101(b)(2)</u> and (b)(3). This listing

refers only to research that is not exempt.)

VIII. Continuing review of research previously approved by the convened IRB as follows:

- 1. where (i) the research is permanently closed to the enrollment of new subjects; (ii) all subjects have completed all research-related interventions; and (iii) the research remains active only for long-term follow-up of subjects; or
- 2. where no subjects have been enrolled and no additional risks have been identified; or
- 3. where the remaining research activities are limited to data analysis.

### This protocol qualifies for expedited review under category

(list the category number)

When writing your protocol, please refer to the "How to Write a Protocol" guide. If applicable to your protocol, please be sure to include the following elements:

- Describe how risks to subjects are minimized (i) by using procedures that are consistent with sound research design and that do not unnecessarily expose subjects to risk, and (ii) whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes.
- 2. Describe how risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result from your study.
- 3. Describe how selection of subjects is equitable.
- 4. If informed consent be sought from each prospective subject or the subject's legally authorized representative.
- 5. Describe how informed consent will be documented or waived.
- 6. Describe how the research plan makes adequate provision for monitoring the data collected to ensure the safety, confidentiality, and privacy of subjects. Describe the data collection process as well as data management and storage.
- 7. Describe adequate provisions that will be used to protect the privacy of subjects and to maintain the confidentiality of data. If confidential data (using personally identifying information) is collected but will be subsequently de-identified, describe how it will be de-identified and how it will be protected before and after de-identification. Describe data storage- how long will you keep the data (including consent forms) and where will it be stored?
- 8. If some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, individuals with impaired decision-making capacity, or economically or educationally disadvantaged persons, describe additional safeguards included in the study to protect the rights and welfare of these subjects.

## B) Additional Protections Categories<sup>1</sup>

(Check all that apply) This research involves:

Pregnant woman/women, human fetuses, and/or neonates (May, where applicable, be exempted from review using applicable exemptions below). Please refer to subpart B of the revised common rule (linked above).

<sup>&</sup>lt;sup>1</sup>Note to IRB Members: Please refer to additional requirements within the common rule at 45 C.F.R. 46 Subparts B, C and D. **Page 6 of 8**Revised 02/04/2025

Biomedical and behavioral research involving prisoners as subjects (May not be exempted from review using applicable exemptions below)

Children involved as subjects (The exemptions at paragraphs (3), (4) and (5) of the listed exemptions may be applied to research involving children as subjects if the conditions of the exemption are met. The exemptions at (2)(i) and (ii) of the listed exemptions only may apply to research involving children as subjects involving educational tests or the observation of public behavior when the investigator(s) do not participate in the activities being observed. The exemption listed at (2)(iii) of the listed exemptions may not be applied to research involving children as subjects.

I. Describe any incentives or benefits investigators or anyone else associated with the proposal are to receive for enrolling subjects and/or completing the study. Describe any conflicts of interest.

II. Attach a copy of your Informed Consent form (if applicable). Consent forms must be submitted in all languages applicable to the study subjects. Attach all data collection instruments.

III. Attach copies of current IRB approval(s) from collaborating institutions; list these institutions:

IV. Required Training for Investigators conducting Human Subject Research:

I attest that I and all co-investigators have read the CDPH IRB document "Required Training for Investigators Conducting Human Subject Research" and have completed the training courses or equivalent certification.

\*Please submit your training certificates with application to CDPH IRB staff.

| Principle Investigator (Print Name)/Signature                                                                                               | Date                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| <b>Institutional Endorsements</b><br>Your endorsement is requested to assure the CD<br>and status of this research activity, and fully appr |                                                                        |
| CDPH Sponsor (Print Name)<br>Title & Program /Signature                                                                                     | Date                                                                   |
| Division Director (Print Name) / Signature                                                                                                  | Date                                                                   |
| <b>Subm</b><br>Chicago Departme<br>Institutional I<br>111 W. Washingtor<br>Chicago,<br>Email: <u>CDPHIRB@</u>                               | nt of Public Health<br>Review Board<br>n Street, 4th Floor<br>IL 60602 |